Fragments, Feedback, and Fast Drugs: When Generative Models Grow a Spine
Opening — Why this matters now Drug discovery has always been the biotech version of slow cooking—long, delicate, expensive, and painfully sensitive to human interpretation. Today, however, rising expectations around AI-accelerated R&D are forcing labs to question not only how fast their models generate molecules, but how quickly those models can learn from expert feedback. The industry’s inconvenient secret is that most “AI-driven design loops” are still bottlenecked by handoffs between chemists and engineers. ...